Restoring tolerance to ß-cells in Type 1 diabetes: Current and emerging strategies.
Cell Immunol
; 380: 104593, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-36081179
ABSTRACT
Type 1 diabetes (T1D) results from insulin insufficiency due to islet death and dysfunction following T cell-mediated autoimmune attack. The technical feasibility of durable, functional autologous islet restoration is progressing such that it presents the most likely long-term cure for T1D but cannot succeed without the necessary counterpart of clinically effective therapeutic strategies that prevent grafted islets' destruction by pre-existing anti-islet T cells. While advances have been made in broad immunosuppression to lower off-target effects, the risk of opportunistic infections and cancers remains a concern, especially for well-managed T1D patients. Current immunomodulatory strategies in development focus on autologous Treg expansion, treatments to decrease antigen presentation and T effector (Teff) activation, and broad depletion of T cells with or without hematopoietic stem cell transplants. Emerging strategies harnessing the intensified DNA damage response present in expanding T cells, exacerbating their already high sensitivity to apoptosis to abate autoreactive Teff cells.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Islotes Pancreáticos
/
Diabetes Mellitus Tipo 1
/
Células Secretoras de Insulina
Límite:
Humans
Idioma:
En
Revista:
Cell Immunol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos